Caribou Biosciences: Advancing Allogeneic Cell Therapy Pipeline and Pivotal Trial Plans Support High-Risk Buy Rating

Citi analyst Yigal Nochomovitz maintained a Buy rating on Caribou Biosciences (CRBU) with an $8.00 price target, citing the company’s advancing clinical pipeline and defined regulatory path. Caribou is progressing a pivotal Phase 2 trial for vispa-cel in second-line large B-cell lymphoma and expects longer-term data from the ANTLER Phase 1 trial this year. The company’s cash reserves of approximately $143 million are expected to fund operations into the second half of 2027, supporting key clinical milestones.